Type 1 Diabetes

In a phase 3 randomized trial, investigators evaluated whether finerenone added to the background renin–angiotensin system blockade, thereby reducing albuminuria in adults with type 1 diabetes and chronic...

A multicenter trial conducted in China found that an artificial intelligence–based insulin clinical decision support system provided glycemic outcomes comparable to standard therapy administered by senior...

As the clinical use of GLP-1 receptor agonists (RA) expands beyond diabetes and obesity, clinicians must balance emerging cardiometabolic and organ-specific benefits with the challenges of persistent...

In adults with type 1 diabetes and obesity using automated insulin delivery, once-weekly semaglutide significantly improved time in range, lowered HbA1c, and reduced body weight by nearly 9 kg compared with...

A retrospective cohort study highlights the potential of GLP-1 receptor agonists to reduce BMI and support glycemic control in adolescents and young adults with type 1 diabetes and obesity without...

Lois E. Donovan, MD, and Denice Feig, MD, MSc, FRCPC, discuss their presentation at the 2025 American Diabetes Association Scientific Sessions, previewing results of a randomized multicenter study which...

Explore how value-based care providers can navigate the clinical and financial impact of emerging therapies, biosimilars, and federal drug pricing reforms.

In this Roundtable Wrap-Up, we offer an abbreviated version of the roundtable discussion on the multidisciplinary approach to managing people with diabetes, the importance of diabetes self-care and...

Following two studies, the FDA has approved the first cellular therapy for the treatment of type 1 diabetes in patients.